Literature DB >> 10930096

Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.

A L Gainer1, I F Parney, K C Petruk, J F Elliott.   

Abstract

We used particle-mediated gene transfer by a custom-built gene gun to transfect two well-established human glioma (D54MG and U251) and melanoma (SK mel 28 and Ed 141) cell lines, as well as two glioma lines locally established from primary patient tumors (Ed 147 and Ed 149). Using beta-galactosidase as a reporter gene, D54MG, U251, Ed 141 and SK mel 28 showed an average transfection efficiency of 15-40%, whereas Ed 147 and Ed 149 had mean transfection efficiencies of 3% and 5% respectively. Twenty-four hours after transfection with the gene encoding human interleukin-12 (IL-12), ELISA was performed on cell supernatants (mean of n = 12 for each cell line). IL-12 expression was extremely variable between the different cell lines, ranging from 52 to 1,151 pg/10(6) cells/24 h. Results were very similar when cells were exposed to 20,000 rads of gamma irradiation 2 h after transfection. When the cell lines were transfected with human granulocyte-macrophage colony-stimulating factor, 24 h levels were: 13.0 (Ed 147), 17.8 (Ed 149), 18.6 (Ed 141), 27.4 (D54MG) and 27.7 ng/10(6) cells/24h (U251). SK mel 28 produced 88.1 ng/10(6) cells/24 h. We conclude that the gene gun can efficiently transfect a variety of immortalized, well-established and locally-established glioma and melanoma cell lines. High dose gamma irradiation does not adversely affect the expression of the foreign gene (IL-12) at 24 h. Significantly, transfected cell lines show different levels of expression depending on the particular gene/plasmid introduced. Therefore, each cell line has to be assessed individually for the level of expression of each introduced gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930096     DOI: 10.1023/a:1006431018563

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

Authors:  A L Rakhmilevich; J Turner; M J Ford; D McCabe; W H Sun; P M Sondel; K Grota; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Human glioma immunobiology in vitro: implications for immunogene therapy.

Authors:  I F Parney; M A Farr-Jones; L J Chang; K C Petruk
Journal:  Neurosurgery       Date:  2000-05       Impact factor: 4.654

3.  Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy.

Authors:  A L Rakhmilevich; J G Timmins; K Janssen; E L Pohlmann; M J Sheehy; N S Yang
Journal:  J Immunother       Date:  1999-03       Impact factor: 4.456

4.  Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.

Authors:  D M Mahvi; P M Sondel; N S Yang; M R Albertini; J H Schiller; J Hank; J Heiner; J Gan; W Swain; R Logrono
Journal:  Hum Gene Ther       Date:  1997-05-01       Impact factor: 5.695

5.  Improved technique for establishing short term human brain tumor cultures.

Authors:  M A Farr-Jones; I F Parney; K C Petruk
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

6.  Eradication of tumor growth via biolistic transformation with allogeneic MHC genes.

Authors:  K M Hui; T F Chia
Journal:  Gene Ther       Date:  1997-08       Impact factor: 5.250

7.  In vivo cytokine gene transfer by gene gun reduces tumor growth in mice.

Authors:  W H Sun; J K Burkholder; J Sun; J Culp; J Turner; X G Lu; T D Pugh; W B Ershler; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model.

Authors:  J G Turner; J Tan; B E Crucian; D M Sullivan; O F Ballester; W S Dalton; N S Yang; J K Burkholder; H Yu
Journal:  Hum Gene Ther       Date:  1998-05-20       Impact factor: 5.695

9.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma.

Authors:  A A Hurwitz; S E Townsend; T F Yu; J A Wallin; J P Allison
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

View more
  1 in total

1.  Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas.

Authors:  Ian F Parney; Lung-Ji Chang; Maxine A Farr-Jones; Chunhai Hao; Michael Smylie; Kenneth C Petruk
Journal:  J Neurooncol       Date:  2006-04-21       Impact factor: 4.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.